The $800k in annual contract spend is a positive signal of commercial traction but is small relative to the $11M market cap. Monitor the next quarterly filing for actual revenue contribution and margin details from these contracts. The stock's historical volatility and poor prior report performance suggest caution.
Price Chart
Executive Summary
Cycurion announced approximately $800,000 in annual contract spend from new commercial and public-health engagements, including a pharmaceutical AI Center of Excellence and a NACCHO award. This is the first public disclosure of these awards and represents a step in the company's stated strategy to expand beyond government into commercial healthcare and life sciences. However, at an $11M market cap, the absolute contract value is modest and does not provide financial details on revenue or profitability impact.
Key Facts
- Announced approximately $800,000 in aggregate annual contract spend from multiple new engagements.
- First public announcement of a pharmaceutical AI Center of Excellence engagement and a new NACCHO award.
- Engagements cover business continuity, cybersecurity assessments, program management, and AI operating capability.
- Company is building commercial healthcare and life-sciences work as a primary growth market while maintaining its government and public-safety franchise.
- No financial statements, revenue figures, or profitability data were provided in the filing.
Financial Impact
Approximately $800,000 in annual contract spend from new engagements, representing roughly 7% of the company's $11M market cap.
Risk Factors
- The $800,000 figure is aggregate annual contract spend, not recognized revenue, and may not fully materialize.
- No financial data on profitability, margins, or cash flow was provided, making it impossible to assess the quality of these wins.
- Historical performance on prior CYCU reports shows significant negative returns at T+5 and T+20, indicating high stock volatility and poor signal reliability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-060880 |
| Exhibit: exhibit991sep32026pressrel.htm | 0001628280-26-060880 |
| Document: 0001628280-26-060880-index-headers.html | 0001628280-26-060880 |
| Document: 0001628280-26-060880-index.html | 0001628280-26-060880 |
| Document: 0001628280-26-060880.txt | 0001628280-26-060880 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 24d ago | 8-K | $3.51 $3.36 | ▼ −4.27% | ▼ −3.61% | $3.82 (+8.83%) |
Aug 28, 2026 5w ago | 8-K | $3.85 $3.54 | ▼ −8.05% | ▼ −8.16% | $3.82 (−0.78%) |
Aug 28, 2026 5w ago | 8-K | $3.85 $3.54 | ▼ −8.05% | ▼ −8.16% | $3.82 (−0.78%) |
Aug 26, 2026 5w ago | Press Release | $0.4586 $3.03 | ▼ −560.71% | ▼ −560.83% | $3.82 (−732.97%) |
Aug 26, 2026 5w ago | Press Release | $0.4586 $3.03 | ▲ +560.71% | ▲ +560.83% | $3.82 (+732.97%) |
Aug 19, 2026 6w ago | 8-K | $5.54 $3.67 | ▼ −33.67% | ▼ −33.28% | $3.82 (−31.00%) |
Aug 18, 2026 6w ago | 8-K | $5.54 $3.67 | ▼ −33.67% | ▼ −33.28% | $3.82 (−31.00%) |
Aug 14, 2026 7w ago | 8-K | $0.6850 $0.6539 | ▼ −4.54% | ▼ −3.17% | $3.82 (+457.66%) |
Aug 14, 2026 7w ago | Press Release | $0.6850 $0.6539 | ▼ −4.54% | ▼ −3.17% | $3.82 (+457.66%) |
Aug 12, 2026 7w ago | 8-K | $4.96 $5.54 | ▲ +11.61% | ▲ +12.06% | $3.82 (−22.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access